

Special Issue

Proteomic and Oncogenic Biomarkers in Gastrointestinal Cancer

Message from the Guest Editors

Gastrointestinal (GI) cancers are among the most prevalent and lethal malignancies worldwide, with aggressive progression and poor prognosis. GI neoplasms are complex diseases with dysregulation of the cellular signaling that controls proliferation and apoptosis. These may be caused by various genetic, genomic, and epigenetic alterations at the cellular or tissue levels. Despite advances, early detection remains challenging. Proteomic and oncogenic biomarkers, especially those identified via proteomic approaches, are vital for understanding tumor initiation, progression, and treatment response. Proteomic analysis reveals changes in protein levels and function, helping to better understand GI cancer progression. The search for new oncogenic and proteomic biomarkers can enhance early diagnosis, prognosis, and personalized treatment. This Special Issue highlights the latest discoveries in these areas, emphasizing their clinical relevance and the importance of biomarker research in improving patient outcomes in GI oncology.

Assistant

Guest Editors

Dr. Marta Lukaszewicz-Zajac

Department of Biochemical Diagnostics, Medical University of Bialystok, 15-089 Bialystok, Poland

Adrianna Romanowicz

Department of Biochemical Diagnostics, Medical University of Bialystok, 15-089 Bialystok, Poland

Deadline for manuscript submissions

30 September 2026



Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/234112

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)





Cancers

an Open Access Journal
by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



[mdpi.com/journal/
cancers](https://mdpi.com/journal/cancers)



About the Journal

Message from the Editor-in-Chief

Cancers (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)